Literature DB >> 11507208

Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.

A J Marozsan1, V S Torre, M Johnson, S C Ball, J V Cross, D J Templeton, M E Quiñones-Mateu, R E Offord, E J Arts.   

Abstract

Aminooxypentane (AOP)-RANTES is a potent inhibitor of nonsyncytium-inducing (NSI), CCR5-tropic (R5) human immunodeficiency virus type 1 (HIV-1) isolates. Although classical chemotactic responses are not induced in primary leukocytes by AOP-RANTES, recent studies suggest that a remnant of cell signaling occurs upon binding of receptor to this compound. We have detected a breakthrough of NSI/R5 replication from the inhibitory effects of high AOP-RANTES concentrations (<100 nM). A stimulation of different primary syncytium-inducing (SI), CXCR4-tropic (X4) HIV-1 isolates was also observed in the presence of AOP-RANTES. This stimulation was also observed after 110 h in PCR and RT-PCR for minus-strand strong-stop DNA and unspliced and multiply spliced RNA, respectively. However, there was significant variability between different SI/X4 or NSI/R5 HIV-1 isolates with regard to this AOP-RANTES-mediated stimulation or breakthrough, respectively. To further define the mechanism(s) responsible for this AOP-RANTES effect, we performed detailed retroviral replication studies with an NSI/R5 (B-92BR021) and SI/X4 (D-92UG021) HIV-1 isolate in the presence of the drug. Treatment of peripheral blood mononuclear cells with 125 nM AOP-RANTES and virus did not alter coreceptor expression, HIV-1 entry, reverse transcription, or mRNA transcription from the long terminal repeat, but it did result in increased HIV-1 integration. This AOP-RANTES-mediated increase in HIV-1 integration was diminished by treatment with pertussis toxin. Phosphorylation of the mitogen-activated protein kinase (MAPK) isoforms, extracellular signal-regulated kinase 1 (ERK1) and ERK2, was increased in a CD4(+) CCR5(+) U87 cell line treated with AOP-RANTES or with an NSI/R5 HIV-1 isolate. These findings suggest that AOP-RANTES may induce a MAPK/ERK signal transduction pathway upon binding to a G-protein-coupled receptor. MAPK/ERK1 and -2 appear to phosphorylate the HIV-1 preintegration complex, a step necessary for nuclear translocation and successful integration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11507208      PMCID: PMC115108          DOI: 10.1128/jvi.75.18.8624-8638.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.

Authors:  M W Smith; M Dean; M Carrington; C Winkler; G A Huttley; D A Lomb; J J Goedert; T R O'Brien; L P Jacobson; R Kaslow; S Buchbinder; E Vittinghoff; D Vlahov; K Hoots; M W Hilgartner; S J O'Brien
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

2.  Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor.

Authors:  I Aramori; S S Ferguson; P D Bieniasz; J Zhang; B Cullen; M G Cullen
Journal:  EMBO J       Date:  1997-08-01       Impact factor: 11.598

3.  Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry.

Authors:  Z Chen; P Zhou; D D Ho; N R Landau; P A Marx
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

Authors:  G Simmons; P R Clapham; L Picard; R E Offord; M M Rosenkilde; T W Schwartz; R Buser; T N Wells; A E Proudfoot
Journal:  Science       Date:  1997-04-11       Impact factor: 47.728

5.  Characterization of RANTES- and aminooxypentane-RANTES-triggered desensitization signals reveals differences in recruitment of the G protein-coupled receptor complex.

Authors:  A J Vila-Coro; M Mellado; A Martín de Ana; C Martínez-A; J M Rodríguez-Frade
Journal:  J Immunol       Date:  1999-09-15       Impact factor: 5.422

6.  Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry.

Authors:  G Simmons; D Wilkinson; J D Reeves; M T Dittmar; S Beddows; J Weber; G Carnegie; U Desselberger; P W Gray; R A Weiss; P R Clapham
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

7.  Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor.

Authors:  C M Hill; H Deng; D Unutmaz; V N Kewalramani; L Bastiani; M K Gorny; S Zolla-Pazner; D R Littman
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

8.  Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection.

Authors:  M Farzan; H Choe; K Martin; L Marcon; W Hofmann; G Karlsson; Y Sun; P Barrett; N Marchand; N Sullivan; N Gerard; C Gerard; J Sodroski
Journal:  J Exp Med       Date:  1997-08-04       Impact factor: 14.307

9.  STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1.

Authors:  F Liao; G Alkhatib; K W Peden; G Sharma; E A Berger; J M Farber
Journal:  J Exp Med       Date:  1997-06-02       Impact factor: 14.307

10.  Change in coreceptor use correlates with disease progression in HIV-1--infected individuals.

Authors:  R I Connor; K E Sheridan; D Ceradini; S Choe; N R Landau
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

View more
  15 in total

1.  HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.

Authors:  Annette N Ratcliff; Wuxian Shi; Eric J Arts
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

2.  Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.

Authors:  Michael A Lobritz; Annette N Ratcliff; Andre J Marozsan; Dawn M Dudley; John C Tilton; Eric J Arts
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

3.  HIV-1 glycoprotein 41 ectodomain induces activation of the CD74 protein-mediated extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to enhance viral infection.

Authors:  Chang Zhou; Lu Lu; Suiyi Tan; Shibo Jiang; Ying-Hua Chen
Journal:  J Biol Chem       Date:  2011-10-28       Impact factor: 5.157

4.  Annulus fibrosus cells express and utilize C-C chemokine receptor 5 (CCR5) for migration.

Authors:  Weijun Liu; David Liu; Justin Zheng; Peng Shi; Po-Hsin Chou; Chundo Oh; Di Chen; Howard S An; Ana Chee
Journal:  Spine J       Date:  2017-01-17       Impact factor: 4.166

5.  G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates.

Authors:  Ali Amara; Aurore Vidy; Genevieve Boulla; Karine Mollier; Javier Garcia-Perez; Jose Alcamí; Cedric Blanpain; Marc Parmentier; Jean-Louis Virelizier; Pierre Charneau; Fernando Arenzana-Seisdedos
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

6.  Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.

Authors:  Kenji Maeda; Hirotomo Nakata; Yasuhiro Koh; Toshikazu Miyakawa; Hiromi Ogata; Yoshikazu Takaoka; Shiro Shibayama; Kenji Sagawa; Daikichi Fukushima; Joseph Moravek; Yoshio Koyanagi; Hiroaki Mitsuya
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

7.  PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.

Authors:  Tatsuyoshi Kawamura; Shannon E Bruse; Awet Abraha; Makoto Sugaya; Oliver Hartley; Robin E Offord; Eric J Arts; Peter A Zimmerman; Andrew Blauvelt; Shannon E Bruce
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.

Authors:  Cristina Pastore; Gastón R Picchio; Francesco Galimi; Richard Fish; Oliver Hartley; Robin E Offord; Donald E Mosier
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

9.  Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5.

Authors:  Xiao-Feng Qin; Dong Sung An; Irvin S Y Chen; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-23       Impact factor: 11.205

10.  Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.

Authors:  Reem Berro; Anila Yasmeen; Ravinder Abrol; Bartosz Trzaskowski; Sarya Abi-Habib; Amy Grunbeck; Danny Lascano; William A Goddard; Per Johan Klasse; Thomas P Sakmar; John P Moore
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.